Wednesday, October 14, 2026

SpaceX's 24-Year Path to IPO Drives $50B Shift to Asset-Backed VC Lending

SpaceX could reach IPO in 2026 after 24 years as a private company, according to Turbine's Mike Hurst. Extended exit timelines are forcing limited partners to borrow against illiquid VC positions rather than wait for traditional liquidity events. Asset-backed lending against LP positions surged as secondary markets demanded 30-40% discounts by 2022.

SpaceX's 24-Year Path to IPO Drives $50B Shift to Asset-Backed VC Lending
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

SpaceX could IPO in 2026 at age 24, illustrating how exit timelines have stretched beyond historical norms, Mike Hurst of Turbine stated. The extended private phase creates liquidity pressure across venture capital markets.

Limited partners face a capital recycling problem. "The lack of significant returns from company exits means fewer dollars for LPs to recycle into new funds," Hurst noted. Public market declines and falling real estate valuations created a denominator effect, shrinking LP allocation capacity for private investments.

VCs responded by slowing capital calls and reducing deployment when valuations reset in 2022. "Founders with excellent products and progress were struggling to raise funds to finish the job," Hurst explained. Traditional fundraising mechanisms stalled despite operational progress at portfolio companies.

Secondary markets offered one exit route but pricing collapsed. "Venture secondary sales started to require significant discounts around 2022, making secondary markets less attractive," Hurst stated. Discounts reached 30-40% of last-round valuations, creating losses LPs couldn't accept.

Asset-backed lending emerged as an alternative. A typical Turbine borrower is a family office with tens of millions in wealth across multiple illiquid positions, Hurst indicated. These LPs borrow against VC holdings at 50-60% loan-to-value ratios, accessing liquidity without selling at steep discounts.

The lending structure benefits multiple parties. LPs gain immediate capital without crystallizing losses. Lenders secure collateral backed by diversified venture portfolios. Portfolio companies avoid down-round signaling from secondary sales.

Market dynamics favor this approach during periods of valuation uncertainty. Private company values remained stable or grew based on operational metrics while public comps fluctuated. The spread between private marks and secondary clearing prices widened to 35-50% in 2022-2023.

Growth capital availability improved as LPs unlocked liquidity through credit lines. Families and institutions borrowed to meet follow-on commitments and new fund capital calls without forced secondary sales. Lending volume against VC/PE positions is estimated to have grown from $15B in 2020 to over $50B by 2025.

Corporate valuations face downward pressure as exit delays extend. Companies once valued for near-term liquidity now trade at discounts reflecting 5-10 year hold periods. The shift reshapes return expectations across private equity strategies.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com